Notice2022-17214
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Multivalent Vaccines for Rabies Virus and Coronaviruses
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 11, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Thomas Jefferson University, located in Philadelphia, Pennsylvania to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 154 (Thursday, August 11, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 154 (Thursday, August 11, 2022)]
[Notices]
[Page 49599]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-17214]
[[Page 49599]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Multivalent Vaccines for Rabies Virus and
Coronaviruses
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive,
sublicensable patent license to Thomas Jefferson University, located in
Philadelphia, Pennsylvania to practice the inventions embodied in the
patent applications listed in the Supplementary Information section of
this notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before August 26, 2022 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and
Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases (NIAID),
5601 Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804, phone
number 301-761-7505, or <a href="/cdn-cgi/l/email-protection#5e293f3a3b70392c3b3b301e30373670393128"><span class="__cf_email__" data-cfemail="70071114155e170215151e301e19185e171f06">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: US Provisional
Patent Application Number 62/318,087, filed 04 April 2016, titled
``Multivalent vaccines for rabies virus and coronaviruses'' (HHS
Reference No. E-128-2016-0-US-01); PCT Application Number PCT/US17/
25623, filed 31 March 2017, titled ``Multivalent vaccines for rabies
virus and coronaviruses'' (HHS Reference No. E-128-2016-0-PCT-02); US
Patent 11,041,170, issued 22 June 2021, titled ``Multivalent vaccines
for rabies virus and coronaviruses'' (HHS Reference No. E-128-2016-0-
US-05); US Patent Application Number 17/307,066, filed 04 May 2021,
titled ``Multivalent vaccines for rabies virus and coronaviruses'' (HHS
Reference No. E-128-2016-0-US-06); EPO Patent Application Number
2017718216.9, filed 31 March 2017, titled ``Multivalent vaccines for
rabies virus and coronaviruses'' (HHS Reference No. E-128-2016-0-EP-
03); and Saudi Arabian Patent Application Number 518400172, filed 04
October 2018, titled ``Multivalent vaccines for rabies virus and
coronaviruses'' (HHS Reference No. E-128-2016-0-SA-04). All rights in
these inventions have been assigned to Thomas Jefferson University,
University of Maryland, Baltimore, and the Government of the United
States of America as represented by the Secretary, Department of Health
& Human Services.
The prospective patent license will be for the purpose of
consolidating the patent rights to Thomas Jefferson University, one of
the co-owners of said rights, for commercial development and marketing.
Consolidation of these co-owned rights is intended to expedite
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
The prospective interinstitutional agreement will include an
exclusive license for NIAID's rights in these jointly owned patents. It
will be sublicensable, and any sublicenses granted by Thomas Jefferson
University will be subject to the provisions of 37 CFR part 401 and
404.
The subject patent rights are related to novel recombinant vaccine
constructs based on a genetically modified, attenuated rabies virus
vaccine vector expressing one or more coronavirus immunogenic
polypeptides. These constructs elicit strong bi-valent immunogenic
responses against both rabies virus and the respective coronavirus in
animal models. The novel rabies virus vector used in these constructs
was developed by Thomas Jefferson University prior to the co-
development of the subject patent rights by Thomas Jefferson
University, the University of Maryland, Baltimore, and NIAID.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and may be granted unless within fifteen (15) days from the date of
this published notice, the National Insitute of Allergy and Infectious
Diseases receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
Complete license applications submitted in response to this Notice
will be presumed to contain business confidential information and any
release of information in these license applications will be made only
as required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: August 5, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-17214 Filed 8-10-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 11, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.